LAFAYETTE, La., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three and nine months ended September 30, 2024.
Operational highlights (all dollar amounts are USD; comparisons are to the period ended September 30, 2023 unless otherwise noted):
Casey Hoyt, Viemed’s CEO, noted, “Viemed continues to earn a trusted place in the home with our high-touch, technology-enabled clinical approach to delivering complex respiratory care services. As a vital link between patients, providers and payers, we are demonstrating Viemed’s value in increasing patient satisfaction, improving compliance, and reducing rehospitalizations. This valuable position is helping us increase the patient population that we can serve for non-invasive ventilation, sleep, staffing and other complementary services.
“The combination of Viemed’s well-earned place in the home, the sales force restructuring initiatives we completed earlier this year, and the operational efficiencies facilitating greater patient compliance are fueling our strong organic revenue growth. The improved outlook for the balance of 2024 is predicated on continued benefits from these sales initiatives and operational efficiencies driving organic growth and greater penetration of our underserved markets through expanded service and home-based product offerings,” added Mr. Hoyt.
Conference Call Details
The Company will host a conference call to discuss third quarter results on Thursday, November 7, 2024 at 12:00 p.m. ET.
Interested parties may participate in the call by dialing:
877-407-6176 (US Toll-Free)
+1 201-689-8451 (International)
Following the conclusion of the call, an audio recording and transcript of the call can be accessed on the Company's website.
ABOUT VIEMED HEALTHCARE, INC.
Viemed is an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, including non-invasive ventilators (NIV), sleep therapy, staffing, and other complementary products and services. Viemed focuses on efficient and effective in-home treatment with clinical practitioners providing therapy, education and counseling to patients in their homes using high-touch and high-tech services. Visit our website at www.viemed.com.
For further information, please contact:
Glen Akselrod
Bristol Capital
905-326-1888
This email address is being protected from spambots. You need JavaScript enabled to view it.
Todd Zehnder
Chief Operating Officer
Viemed Healthcare, Inc.
337-504-3802
This email address is being protected from spambots. You need JavaScript enabled to view it.
Forward-Looking Statements
Certain statements contained in this press release may constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or “forward-looking information” as such term is defined in applicable Canadian securities legislation (collectively, “forward-looking statements”). Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “projects”, or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results “will”, “should”, “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company's net revenue guidance for the fourth quarter, are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which the Company operates; significant capital requirements and operating risks that the Company may be subject to; the ability of the Company to implement business strategies and pursue business opportunities; volatility in the market price of the Company's common shares; the state of the capital markets; the availability of funds and resources to pursue operations; inflation; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers; granting of permits and licenses in a highly regulated business; competition; disruptions in or attacks (including cyber-attacks) on the Company's information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the Company’s status as an emerging growth company; and the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, and claims resulting from such events or concerns; as well as those risk factors discussed or referred to in the Company’s disclosure documents filed with the U.S. Securities and Exchange Commission (the “SEC”) available on the SEC’s website at www.sec.gov, including the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada available at www.sedar.com. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.
| VIEMED HEALTHCARE, INC. | ||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
| (Expressed in thousands of U.S. Dollars, except share amounts) | ||||||||
| (Unaudited) | ||||||||
| At September 30, 2024 | At December 31, 2023 | |||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 11,347 | $ | 12,839 | ||||
| Accounts receivable, net | 27,051 | 18,451 | ||||||
| Inventory | 4,311 | 4,628 | ||||||
| Prepaid expenses and other assets | 4,989 | 2,449 | ||||||
| Total current assets | $ | 47,698 | $ | 38,367 | ||||
| Long-term assets | ||||||||
| Property and equipment, net | 74,397 | 73,579 | ||||||
| Finance lease right-of-use assets | 70 | 401 | ||||||
| Operating lease right-of-use assets | 2,758 | 2,872 | ||||||
| Equity investments | 1,794 | 1,680 | ||||||
| Debt investment | 875 | 2,219 | ||||||
| Deferred tax asset | 8,065 | 4,558 | ||||||
| Identifiable intangibles, net | 880 | 567 | ||||||
| Goodwill | 32,989 | 29,765 | ||||||
| Other long-term assets | — | 887 | ||||||
| Total long-term assets | $ | 121,828 | $ | 116,528 | ||||
| TOTAL ASSETS | $ | 169,526 | $ | 154,895 | ||||
| LIABILITIES | ||||||||
| Current liabilities | ||||||||
| Trade payables | $ | 6,007 | $ | 4,180 | ||||
| Deferred revenue | 6,819 | 6,207 | ||||||
| Income taxes payable | 2,077 | 2,153 | ||||||
| Accrued liabilities | 19,918 | 17,578 | ||||||
| Finance lease liabilities, current portion | 69 | 256 | ||||||
| Operating lease liabilities, current portion | 742 | 678 | ||||||
| Current portion of long-term debt | 812 | 1,072 | ||||||
| Total current liabilities | $ | 36,444 | $ | 32,124 | ||||
| Long-term liabilities | ||||||||
| Accrued liabilities | 652 | 558 | ||||||
| Finance lease liabilities, less current portion | — | 132 | ||||||
| Operating lease liabilities, less current portion | 1,985 | 2,184 | ||||||
| Long-term debt | 3,650 | 6,002 | ||||||
| Total long-term liabilities | $ | 6,287 | $ | 8,876 | ||||
| TOTAL LIABILITIES | $ | 42,731 | $ | 41,000 | ||||
| Commitments and Contingencies | — | — | ||||||
| SHAREHOLDERS' EQUITY | ||||||||
| Common stock - No par value: unlimited authorized; 38,932,247 and 38,506,161 issued and outstanding as of September 30, 2024 and December 31, 2023, respectively | 22,749 | 18,702 | ||||||
| Additional paid-in capital | 16,831 | 15,698 | ||||||
| Retained earnings | 85,379 | 79,495 | ||||||
| TOTAL VIEMED HEALTHCARE, INC.'S SHAREHOLDERS' EQUITY | $ | 124,959 | $ | 113,895 | ||||
| Noncontrolling interest in subsidiary | 1,836 | — | ||||||
| TOTAL SHAREHOLDERS' EQUITY | 126,795 | 113,895 | ||||||
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ | 169,526 | $ | 154,895 | ||||
| VIEMED HEALTHCARE, INC. | ||||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF INCOME | ||||||||||||||||
| (Expressed in thousands of U.S. Dollars, except outstanding shares and per share amounts) | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Revenue | $ | 58,004 | $ | 49,402 | $ | 163,562 | $ | 132,269 | ||||||||
| Cost of revenue | 23,633 | 18,840 | 66,497 | 51,597 | ||||||||||||
| Gross profit | $ | 34,371 | $ | 30,562 | $ | 97,065 | $ | 80,672 | ||||||||
| Operating expenses | ||||||||||||||||
| Selling, general and administrative | 26,671 | 23,654 | 77,988 | 63,979 | ||||||||||||
| Research and development | 757 | 593 | 2,265 | 2,131 | ||||||||||||
| Stock-based compensation | 1,712 | 1,453 | 4,764 | 4,315 | ||||||||||||
| Depreciation and amortization | 348 | 419 | 1,140 | 957 | ||||||||||||
| Loss (gain) on disposal of property and equipment | (469 | ) | 278 | (801 | ) | 373 | ||||||||||
| Other expense (income), net | (276 | ) | (41 | ) | 261 | (124 | ) | |||||||||
| Income from operations | $ | 5,628 | $ | 4,206 | $ | 11,448 | $ | 9,041 | ||||||||
| Non-operating income and expenses | ||||||||||||||||
| Income (expense) from investments | 96 | 270 | (954 | ) | 442 | |||||||||||
| Interest expense, net | (225 | ) | (237 | ) | (629 | ) | (168 | ) | ||||||||
| Net income before taxes | 5,499 | 4,239 | 9,865 | 9,315 | ||||||||||||
| Provision for income taxes | 1,594 | 1,320 | 2,880 | 2,549 | ||||||||||||
| Net income | $ | 3,905 | $ | 2,919 | $ | 6,985 | $ | 6,766 | ||||||||
| Net income attributable to noncontrolling interest | 27 | — | 36 | — | ||||||||||||
| Net income attributable to Viemed Healthcare, Inc. | $ | 3,878 | $ | 2,919 | $ | 6,949 | $ | 6,766 | ||||||||
| Net income per share | ||||||||||||||||
| Basic | $ | 0.10 | $ | 0.08 | $ | 0.18 | $ | 0.18 | ||||||||
| Diluted | $ | 0.10 | $ | 0.07 | $ | 0.17 | $ | 0.17 | ||||||||
| Weighted average number of common shares outstanding: | ||||||||||||||||
| Basic | 38,870,823 | 38,438,058 | 38,803,887 | 38,307,343 | ||||||||||||
| Diluted | 40,779,414 | 40,420,615 | 40,702,001 | 40,391,729 | ||||||||||||
| VIEMED HEALTHCARE, INC. | ||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
| (Expressed in thousands of U.S. Dollars) | ||||||||
| (Unaudited) | ||||||||
| Nine Months Ended September 30, | ||||||||
| 2024 | 2023 | |||||||
| Cash flows from operating activities | ||||||||
| Net income | $ | 6,985 | $ | 6,766 | ||||
| Adjustments for: | ||||||||
| Depreciation and amortization | 19,002 | 15,943 | ||||||
| Stock-based compensation expense | 4,764 | 4,315 | ||||||
| Distributions of earnings received from equity method investments | 147 | 833 | ||||||
| Income from equity method investments | (261 | ) | (442 | ) | ||||
| Loss (income) from debt investment | 1,344 | (164 | ) | |||||
| Loss (gain) on disposal of property and equipment | (801 | ) | 373 | |||||
| Amortization of deferred financing costs | 135 | — | ||||||
| Deferred income tax benefit | (3,507 | ) | (791 | ) | ||||
| Changes in working capital: | ||||||||
| Accounts receivable, net | (8,213 | ) | (533 | ) | ||||
| Inventory | 583 | (514 | ) | |||||
| Prepaid expenses and other assets | 340 | 1,193 | ||||||
| Trade payables | 747 | (255 | ) | |||||
| Deferred revenue | 489 | 859 | ||||||
| Accrued liabilities | 2,424 | 4,086 | ||||||
| Income tax payable/receivable | (76 | ) | 259 | |||||
| Net cash provided by operating activities | $ | 24,102 | $ | 31,928 | ||||
| Cash flows from investing activities | ||||||||
| Purchase of property and equipment | (25,942 | ) | (18,161 | ) | ||||
| Investment in equity investments | — | (7 | ) | |||||
| Cash paid for acquisitions, net of cash acquired | (2,999 | ) | (28,580 | ) | ||||
| Proceeds from sale of property and equipment | 7,440 | 2,128 | ||||||
| Net cash used in investing activities | $ | (21,501 | ) | $ | (44,620 | ) | ||
| Cash flows from financing activities | ||||||||
| Proceeds from exercise of options | 416 | 1,234 | ||||||
| Proceeds from term notes | — | 5,000 | ||||||
| Principal payments on term notes | (954 | ) | (2,746 | ) | ||||
| Proceeds from revolving credit facilities | 3,000 | 8,000 | ||||||
| Payments on revolving credit facilities | (5,000 | ) | (5,005 | ) | ||||
| Payments for debt issuance costs | (171 | ) | — | |||||
| Shares redeemed to pay income tax | (1,065 | ) | (595 | ) | ||||
| Repayments of finance lease liabilities | (319 | ) | (32 | ) | ||||
| Net cash provided by (used in) financing activities | $ | (4,093 | ) | $ | 5,856 | |||
| Net decrease in cash and cash equivalents | (1,492 | ) | (6,836 | ) | ||||
| Cash and cash equivalents at beginning of year | 12,839 | 16,914 | ||||||
| Cash and cash equivalents at end of period | $ | 11,347 | $ | 10,078 | ||||
| Supplemental disclosures of cash flow information | ||||||||
| Cash paid during the period for interest | $ | 745 | $ | 497 | ||||
| Cash paid during the period for income taxes, net of refunds | $ | 6,416 | $ | 3,218 | ||||
| Supplemental disclosures of non-cash transactions | ||||||||
| Equipment and other fixed asset purchases payable at end of period | $ | 2,854 | $ | 2,598 | ||||
| Equipment sales receivable at end of period | $ | 1,683 | $ | — | ||||
Non-GAAP Financial Measures
This press release refers to “Adjusted EBITDA”, which is a financial measure that is not prepared in accordance with generally accepted accounting principles in the United States ("GAAP"). Adjusted EBITDA should be considered in addition to, not as a substitute for, or superior to, financial measures calculated in accordance with U.S. GAAP. Management believes Adjusted EBITDA provides helpful information with respect to the Company’s operating performance as viewed by management, including a view of the Company’s business that is not dependent on the impact of the Company’s capitalization structure and items that are not part of the Company’s day-to-day operations. Management uses Adjusted EBITDA (i) to compare the Company’s operating performance on a consistent basis, (ii) to calculate incentive compensation for the Company’s employees, (iii) for planning purposes, including the preparation of the Company’s internal annual operating budget, and (iv) to evaluate the performance and effectiveness of the Company’s operational strategies. Accordingly, management believes that Adjusted EBITDA provides useful information in understanding and evaluating the Company’s operating performance in the same manner as management. Adjusted EBITDA is not a measurement of the Company’s financial performance under U.S. GAAP and should not be considered as an alternative to revenue or net income, as applicable, or any other performance measures derived in accordance with U.S. GAAP. Adjusted EBITDA has limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of the Company’s operating results as reported under U.S. GAAP. Adjusted EBITDA does not reflect the impact of certain cash charges resulting from matters the Company considers not to be indicative of ongoing operations; and other companies in the Company’s industry may calculate Adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure. In calculating Adjusted EBITDA, certain items (mostly non-cash) are excluded from net income including depreciation and amortization of capitalized assets, net interest expense (income), stock based compensation, transaction costs, impairment of assets, and taxes.
The following table is a reconciliation of net income (loss), the most directly comparable U.S. GAAP measure, to Adjusted EBITDA, on a historical basis for the periods indicated:
| VIEMED HEALTHCARE, INC. | ||||||||||||||||||||||||
| Reconciliation of Net Income to Non-GAAP Adjusted EBITDA | ||||||||||||||||||||||||
| (Expressed in thousands of U.S. Dollars) | ||||||||||||||||||||||||
| (Unaudited) | ||||||||||||||||||||||||
| For the quarter ended | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | ||||||||||||||||
| Net income attributable to Viemed Healthcare, Inc. | $ | 3,878 | $ | 1,468 | $ | 1,603 | $ | 3,477 | $ | 2,919 | $ | 2,330 | $ | 1,517 | $ | 2,438 | ||||||||
| Add back: | ||||||||||||||||||||||||
| Depreciation & amortization | 6,408 | 6,309 | 6,285 | 5,918 | 5,975 | 5,207 | 4,762 | 4,373 | ||||||||||||||||
| Interest expense (income) | 225 | 254 | 150 | 256 | 237 | (20 | ) | (49 | ) | 32 | ||||||||||||||
| Stock-based compensation(a) | 1,712 | 1,620 | 1,432 | 1,534 | 1,453 | 1,471 | 1,391 | 1,317 | ||||||||||||||||
| Transaction costs(b) | 12 | 221 | 110 | 61 | 177 | 94 | 206 | — | ||||||||||||||||
| Impairment of assets(c) | 125 | 2,173 | — | — | — | — | — | — | ||||||||||||||||
| Income tax expense | 1,594 | 768 | 518 | 1,599 | 1,320 | 728 | 501 | 1,146 | ||||||||||||||||
| Adjusted EBITDA | $ | 13,954 | $ | 12,813 | $ | 10,098 | $ | 12,845 | $ | 12,081 | $ | 9,810 | $ | 8,328 | $ | 9,306 | ||||||||
(a) Represents non-cash, equity-based compensation expense associated with option and RSU awards.
(b) Represents transaction costs and expenses related to acquisition and integration efforts associated with recently announced or completed acquisitions.
(c) Represents impairments of the fair value of investment and litigation-related assets.
| VIEMED HEALTHCARE, INC. | ||||||||||||||||||||||||
| Key Financial and Operational Information | ||||||||||||||||||||||||
| (Expressed in thousands of U.S. Dollars, except vent patients) | ||||||||||||||||||||||||
| (Unaudited) | ||||||||||||||||||||||||
| For the quarter ended | September 30,2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | ||||||||||||||||
| Financial Information: | ||||||||||||||||||||||||
| Revenue | $ | 58,004 | $ | 54,965 | $ | 50,593 | $ | 50,739 | $ | 49,402 | $ | 43,311 | $ | 39,556 | $ | 37,508 | ||||||||
| Gross Profit | $ | 34,371 | $ | 32,892 | $ | 29,802 | $ | 32,111 | $ | 30,562 | $ | 26,106 | $ | 24,004 | $ | 22,896 | ||||||||
| Gross Profit % | 59 | % | 60 | % | 59 | % | 63 | % | 62 | % | 60 | % | 61 | % | 61 | % | ||||||||
| Net Income | $ | 3,905 | $ | 1,477 | $ | 1,603 | $ | 3,477 | $ | 2,919 | $ | 2,330 | $ | 1,517 | $ | 2,438 | ||||||||
| Cash (As of) | $ | 11,347 | $ | 8,807 | $ | 7,309 | $ | 12,839 | $ | 10,078 | $ | 10,224 | $ | 23,544 | $ | 16,914 | ||||||||
| Total Assets (As of) | $ | 169,526 | $ | 163,947 | $ | 154,875 | $ | 154,895 | $ | 149,400 | $ | 149,117 | $ | 124,634 | $ | 117,043 | ||||||||
| Adjusted EBITDA(1) | $ | 13,954 | $ | 12,813 | $ | 10,098 | $ | 12,845 | $ | 12,081 | $ | 9,810 | $ | 8,328 | $ | 9,306 | ||||||||
| Operational Information: | ||||||||||||||||||||||||
| Vent Patients(2) | 11,374 | 10,905 | 10,450 | 10,327 | 10,244 | 10,005 | 9,337 | 9,306 | ||||||||||||||||
(1) Refer to "Non-GAAP Financial Measures" section above for definition of Adjusted EBITDA.
(2) Vent Patients represents the number of active ventilator patients on recurring billing service at the end of each calendar quarter.
The revenues from each major source are summarized in the following table:
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Revenue from rentals | ||||||||||||||||
| Ventilator rentals, non-invasive and invasive | $ | 31,772 | $ | 28,322 | $ | 91,404 | $ | 79,181 | ||||||||
| Other home medical equipment rentals | 12,459 | 11,119 | 35,604 | 26,441 | ||||||||||||
| Revenue from sales and services | ||||||||||||||||
| Equipment and supply sales | 8,440 | 7,742 | 21,956 | 19,287 | ||||||||||||
| Service revenues | 5,333 | 2,219 | 14,598 | 7,360 | ||||||||||||
| Total revenues | $ | 58,004 | $ | 49,402 | $ | 163,562 | $ | 132,269 | ||||||||
| Last Trade: | US$9.14 |
| Daily Change: | 0.34 3.86 |
| Daily Volume: | 328,449 |
| Market Cap: | US$354.910M |
April 02, 2024 March 06, 2024 November 07, 2023 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
